Drug Discovery & DevelopmentMerrimack heads to the FDA after scoring positive PhIII for pancreatic cancerFierceBiotechMerrimack Pharmaceuticals got roughed up when it went public back in 2012, then took it on the chin–twice–when one of their cancer drugs partnered with Sanofi ($SNY) failed two mid-stage studies. But this morning its stock price sailed up about 90% on the …Small Gains for Healthcare Sector; Merrimack Pharmaceuticals Soars After …NASDAQUPDATE 2-Merrimack shares soar as cancer drug combo improves survivalReutersMerrimack Pharmaceuticals (MACK) Posts Quarterly ResultsWKRB NewsBusinessweek -WallStreetPR -TheStreet.comall 41 news articles …Read Full Story
Merrimack heads to the FDA after scoring positive PhIII for pancreatic cancer - FierceBiotech
Real Estate of Cebu
